1. Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms

4. Overview

5. Predictors for Disease Responsiveness to Novel Agents

6. Predictors for Disease Responsiveness to Novel Agents (cont)

7. Predictors for Disease Responsiveness With Idelalisib

8. Predictors for Disease Responsiveness With Ibrutinib

9. R/R CLL: Ibrutinib

10. R/R CLL: Venetoclax

11. Treatment Considerations: Del17p or TP53mut

12. Resistant Subclones Precede Relapse During Ibrutinib Therapy

13. Treatment Considerations: Del17p or TP53mut (cont)

14. Clinicopathological Features and Outcomes of Progression With Venetoclax

15. Molecular Basis for Relapse or Progression on Idelalisib

16. Individualizing Therapy in Challenging Cases

17. Patients With Del17p or TP53mut

18. Treatment of R/R CLL in Elderly Patients

19. RESONATE and RESONATE-2 Studies With Ibrutinib: Adverse Events by Age

20. Treatment of R/R CLL in Elderly Patients (cont)

21. Pooled Analysis of Venetoclax Efficacy in Patients With R/R CLL

22. Bulky Disease

23. Bulky Disease: del11q

24. Venetoclax Monotherapy After Ibrutinib or Idelalisib

25. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax

26. Treatment Intolerance

27. Role of Allogeneic HSCT in R/R CLL

28. Richter Syndrome: Emerging Treatment Options

29. Combined Immune Approaches

30. Combination Therapy: Addition of Oral Small Molecules to Chemoimmunotherapy

31. Concluding Remarks

32. Concluding Remarks (cont)

33. Abbreviations

34. Abbreviations (cont)